AUTHOR=Cai Yuhan , Han Qin , Guo Hongyan 

TITLE=Identifying clinical features and molecular characteristics of the endometrial clear cell carcinoma

JOURNAL=Frontiers in Oncology

VOLUME=Volume 13 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1286176

DOI=10.3389/fonc.2023.1286176

ISSN=2234-943X

ABSTRACT=The aim was to verify the TCGA subtypes in endometrial clear cell carcinoma (ECCC) and find its clinical and molecular characteristics.We summarized and compared the clinical features of 28 clear cell carcinoma and 112 endometrioid carcinoma patients. Of the 28 ECCCs, 19 underwent TCGA classification and other markers (ER, PR, ARID1A, ARIB1B, TAF1 and HER-2) were also detected by IHC and outcomes were assessed.Compared to endometrioid carcinoma, ECCC had an elder onset age (median age was 64.5 years, range 31-81 years), higher rate of myometrial invasion (42.8% vs 21.5% in endometrioid carcionma) and LVSI (33% vs 16%) and more advanced FIGO stage. And among ECCCs, LVSI was a poor prognostic factor. TCGA classification was underwent in 19 ECCCs: 2 cases (10.5%) POLEmut, 3 MMRd (15.8%), 11 p53wt (57.9%) and 3 p53abn (15.8%). Of the 19 ECCCs, 6 cases (31.6%) showed HER-2 positive expression and 8 cases (42.1%) had TAF1 expression loss. ECCCs possessed HER-2 and TAF1 positive expression simultaneously had a worse outcome.Our study summarized clinical features of ECCC. Outcomes of ECCC patients with TCGA subtypes were different from those in endometrioid carcinoma. HER-2 and TAF1 might become new prognostic factors.